Essex Bio-Technology (HKSE:01061) Construction In Progress: HK$256 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01061 Essex Bio-Technology Ltd HKSE:01061
86 GF Score
Price HK$2.29
GF Value HK$3.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Essex Bio-Technology Construction In Progress?

Essex Bio-Technology HKSE:01061 +0.88% 86 Construction In Progress is HK$256 Mil as of Jun. 2026. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Essex Bio-Technology's quarterly construction in progress declined from Jun. 2025 (HK$227 Mil) to Dec. 2025 (HK$221 Mil) but then increased from Dec. 2025 (HK$221 Mil) to Jun. 2026 (HK$256 Mil).

Essex Bio-Technology's annual construction in progress increased from Dec. 2023 (HK$151 Mil) to Dec. 2024 (HK$188 Mil) and increased from Dec. 2024 (HK$188 Mil) to Dec. 2025 (HK$221 Mil).

Essex Bio-Technology Construction In Progress Historical Data

* Premium members only.

The historical data trend for Essex Bio-Technology's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Essex Bio-Technology Construction In Progress Chart

Essex Bio-Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.95 134.05 151.10 187.57 221.15

Essex Bio-Technology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 138.75 187.57 227.28 221.15 255.65
HKSE:01061
86GF Score
Essex Bio-Technology Ltd HKSE:01061
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Essex Bio-Technology Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$256 Mil mean?
Essex Bio-Technology (HKSE:01061) has a Construction In Progress of HK$256 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Essex Bio-Technology and its competitors.
Is Essex Bio-Technology's Construction In Progress too high?
Essex Bio-Technology's current Construction In Progress is HK$256 Mil. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Construction In Progress compare to ZTS?
Essex Bio-Technology's Construction In Progress of HK$256 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Essex Bio-Technology and its competitors. Essex Bio-Technology's current Construction In Progress is HK$256 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Construction In Progress is HK$256 Mil. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Construction In Progress is HK$256 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?

Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued. The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13. GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.

Key valuation signals for HKSE:01061:

  • Construction In Progress: HK$256 Mil
  • GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Essex Bio-Technology Business Description

Address No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score

Get the complete analysis for HKSE:01061

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.29
Price
HK$3.13
GF Value